At the same time, therapies developed with other primary goals can actually be useful in improving hepatic functionality and lipid status, gaining interest also for the treatment of NAFLD, i.e., incretin agonists (GLP-1 in particular) and THRβ agonists. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatotic liver disease.